ライフサイエンスコーパス: carvedilol

1 at does not seem to occur with metoprolol or carvedilol.

2 patients were assigned to receive placebo or carvedilol.

3 ailure and systolic dysfunction treated with carvedilol.

4 ontribute to the cardioprotective effects of carvedilol.

5 ad heart failure at study entry; 34 received carvedilol.

6 ling by the ryanodine stabilizer JTV-519 and carvedilol.

7 tentially be suppressed by carvedilol or (R)-carvedilol.

8 of the patients on metoprolol and in 23% on carvedilol.

9 h metoprolol (0.15% [0.04%]; P<.001) but not carvedilol (0.02% [0.04%]; P = .65).

10 to twice-daily dosing with placebo, low-dose carvedilol (0.2 mg/kg per dose if weight <62.5 kg or 12.

11 Moderate-quality evidence supports carvedilol (0.21; 0.08-0.56) and VBL monotherapy (0.33;

12 dose if weight > or =62.5 kg), or high-dose carvedilol (0.4 mg/kg per dose if weight <62.5 kg or 25

13 Carvedilol (1 mg/kg IV), administered 5 minutes before r

14 ial in normal subjects (single dose of 25 mg carvedilol, 100 mg metoprolol tartrate, and placebo).

15 ibernators, respectively) but increased with carvedilol (2.5 [0.9] and 3.2 [0.8], respectively; p<0.0

16 ated cardiomyopathy (DCM) were randomized to carvedilol (25 mg twice daily, Coreg, Glaxo Smith Kline,

17 e, heart rates were significantly reduced by carvedilol (308 +/- 25 versus 351 +/- 31 beats per minut

18 p (47%) than in the lisinopril (37%) and the carvedilol (31%) groups.

19 l medications; atenolol: 92 mg versus 68 mg; carvedilol: 44 mg versus 20 mg; metoprolol: 80 mg versus

20 In contrast, carvedilol (5 mg/kg, intraperitoneally) administered 15

21 hanged (15%); among 103 patients assigned to carvedilol, 58 improved (56%), 25 worsened (24%), and 20

22 Of the patients treated with carvedilol, 8 underwent exercise training and 8 remained

23 Insulin sensitivity improved with carvedilol (-9.1%; P = .004) but not metoprolol (-2.0%;

24 mbined risk of death or hospitalization with carvedilol (95 percent confidence interval, 13 to 33 per

25 5 percent decrease in the risk of death with carvedilol (95 percent confidence interval, 19 to 48 per

26 tion and improves its functional response to carvedilol, a beta blocker currently used in the treatme

27 holesterolemia and determined the effects of carvedilol, a beta-blocker with free radical-scavenging

28 Carvedilol, a currently prescribed nonselective beta-blo

29 Carvedilol, a known antioxidant did not decrease 4HNE ad

30 Carvedilol, a new vasodilating beta-adrenoceptor antagon

31 Carvedilol, a nonselective beta-blocker, may be more eff

32 One drug, carvedilol, a nonsubtype-selective betaAR antagonist, ha

33 Carvedilol, a novel vasodilating beta-blocker with antio

34 derstand the full otoprotective potential of carvedilol, a series of 18 analogues were prepared and e

35 hat the beta-arrestin-biased betaAR agonist, carvedilol, activates cellular pathways in the heart.

36 Carvedilol added to angiotensin-converting enzyme inhibi

37 Metoprolol and carvedilol administered 6 d after MI for 4 wk each incre

38 Carvedilol also decreased the mean number of hospitaliza

39 Carvedilol also improved functional class, ejection frac

40 Surprisingly, the betaAR antagonist carvedilol also induced ubiquitination and lysosomal tra

41 ction fraction < 45% (n = 49 patients; 24 on carvedilol and 25 on placebo), carvedilol showed attenua

42 cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < .02).

43 ll-cause mortality was 34% (512 of 1511) for carvedilol and 40% (600 of 1518) for metoprolol (hazard

44 th internalized beta(2)ARs was stabilized by carvedilol and did not involve beta-arrestin.

45 hen randomized to treatment with and without carvedilol and followed until the time of surgery (mean

46 admission occurred in 1116 (74%) of 1511 on carvedilol and in 1160 (76%) of 1518 on metoprolol (0.94

47 ic actions of the aforementioned drugs, with carvedilol and JTV-519 (but not flecainide or riluzole)

48 the efficacy of mixed adrenoceptor blockers carvedilol and labetalol, and the atypical antipsychotic

49 We aimed to compare the effects of carvedilol and metoprolol on clinical outcome.

50 The impact of carvedilol and metoprolol on inappropriate therapy in he

51 of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropria

52 Carvedilol and metoprolol showed parallel beneficial eff

53 we examined the effects of standard doses of carvedilol and metoprolol succinate (metoprolol controll

54 ssed the relative efficacy of equal doses of carvedilol and metoprolol succinate on survival in multi

55 e to infused Ang II in patients treated with carvedilol and metoprolol, a selective beta-antagonist.

56 lol, carvedilol, and metoprolol; 2 of these, carvedilol and metoprolol, have Food and Drug Administra

57 a on the new vasodilating beta-blockers (eg, carvedilol and nebivolol).

58 Although there was no difference between the carvedilol and placebo groups in the number of patients

59 Carvedilol and propranolol had no effect on basal cAMP l

60 We also showed that racemic carvedilol and the non-beta-blocking carvedilol enantiom

61 At higher concentrations, both carvedilol and this derivative were toxic in cochlear cu

62 h greater responsiveness for metoprolol than carvedilol) and beta(1)-adrenergic receptor Arg389Gly po

63 curred in 32% of patients on placebo, 29% on carvedilol, and 30% on lisinopril.

64 available in the United States, bisoprolol, carvedilol, and metoprolol; 2 of these, carvedilol and m

65 ckers (NSBB), isosorbide-mononitrate (ISMN), carvedilol, and variceal band ligation (VBL), alone or i

66 Carvedilol antagonized the response to exogenous norepin

67 CGP 12177 and carvedilol are potent antagonists at the catecholamine s

68 Nebivolol and carvedilol are third-generation beta-adrenoreceptor anta

69 an combined non-selective beta-blockade with carvedilol at the maximally recommended dose.

70 were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for u

71 Acute administration of carvedilol attenuates the vasoconstriction response to a

72 - + beta1,2,3-adrenergic receptor antagonist carvedilol before or after a thermogenic challenge of MD

73 ve), metoprolol+doxazosin (beta1/alpha1), or carvedilol (beta1/beta2/alpha1).

74 Chronic effects (25 mg carvedilol BID versus 200 mg extended-release metoprolol

75 ed that the E3 ligase MARCH2 interacted with carvedilol-bound beta(2)AR.

76 were started on one of three beta-blockers (carvedilol, bucindolol or metoprolol) and the dose was a

77 F patients have better responses not only to carvedilol but to certain other beta blockers as well.

78 a pronounced dose-dependent relationship in carvedilol, but not in metoprolol.

79 ear dose-dependent relationship was found in carvedilol, but not in metoprolol.

80 model, we demonstrate chronic treatment with carvedilol, but not other beta-blockers, indeed enhances

81 ent of the hypercholesterolemic rabbits with carvedilol, but not propranolol, significantly preserved

82 on fraction was not altered significantly by carvedilol, but stroke volume was higher at pre-hospital

83 Here we show that only alprenolol (Alp) and carvedilol (Car) induce beta(1)AR-mediated transactivati

84 cations included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosp

85 Carvedilol, classically defined as a betaAR antagonist,

86 ation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0

87 y, in hibernators versus non-hibernators, on carvedilol compared with placebo.

88 with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.

89 Moreover, when administered 1 hr after MDMA, carvedilol completely reversed established hyperthermia

90 Here, we tested whether carvedilol could activate beta-arrestin-mediated miR mat

91 tudy, we investigated whether treatment with carvedilol could enhance skeletal muscle strength via be

92 delaying abilities of intestinal mucus using carvedilol (CVDL) and piroxicam (PXM) as model drugs.

93 In normal subjects, carvedilol decreased forearm vascular resistance respons

94 For heart failure hospital admissions, carvedilol decreased mean length of stay by 37% (p = 0.0

95 he alpha- and beta-adrenergic blocking agent carvedilol demonstrated a significant survival advantage

96 Carvedilol did not improve the 4HNE-mediated decrease in

97 nal trials are required to determine whether carvedilol differs in its effect from other agents.

98 g 16 clinically relevant betaAR antagonists, carvedilol displays a unique profile of in vitro signali

99 subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor respon

100 These preliminary results suggest that carvedilol does not significantly improve clinical heart

101 The change in LVEF was also influenced by carvedilol dose, etiology of heart failure, baseline hea

102 racemic carvedilol and the non-beta-blocking carvedilol enantiomer, (R)-carvedilol, suppressed sponta

103 Interestingly, carvedilol enhanced skeletal muscle contractility despit

104 Average carvedilol equivalent dose was 29.1+/-17.0 mg daily.

105 he BB dose at baseline was standardized with carvedilol equivalents and analyzed as a continuous vari

106 Our results suggest that carvedilol extends survival compared with metoprolol.

107 rrhythmias by beta-blockers (propranolol and carvedilol), flecainide, and the neuronal sodium-channel

108 ind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chro

109 placebo and 1156 patients to treatment with carvedilol for a mean period of 10.4 months, during whic

110 trials of tacrine for Alzheimer disease and carvedilol for congestive heart failure typify the use o

111 ratios of the relative risks associated with carvedilol for these two outcome variables in black as c

112 lure, which treated patients with placebo or carvedilol for up to 15 months (median, 6.5 months).

113 that: (i) The beta-AR antagonists nadolol or carvedilol, given as a single i.v. injection (acute trea

114 Patients in the carvedilol group also spent 27% fewer days in the hospit

115 found that 304 (27.2%) patients died in the carvedilol group and 1066 (36.8%) in the metoprolol grou

116 Compared with placebo, patients in the carvedilol group had a greater frequency of symptomatic

117 , all-cause mortality alone was lower in the carvedilol group than in the placebo group (116 [12%] vs

118 mproved and fewer patients felt worse in the carvedilol group than in the placebo group after 6 month

119 Fewer patients in the carvedilol group than in the placebo group withdrew beca

120 orsened outcome for patients in the combined carvedilol group vs the placebo group was 0.79 (95% CI,

121 he placebo group and 22 to 975 (2.3%) in the carvedilol group, giving a carvedilol/placebo hazard rat

122 e placebo group, as compared with 425 in the carvedilol group.

123 s in the placebo group and 130 deaths in the carvedilol group.

124 stically significant only in the much larger carvedilol group.

125 -related and was present in both placebo and carvedilol groups, although the effect was statistically

126 d pressure response in either the placebo or carvedilol groups.

127 primary adult murine cardiomyocytes, whereas carvedilol had no efficacy.

128 t rate reductions, short-term treatment with carvedilol had superior hemodynamic and metabolic effect

129 Carvedilol has a powerful antiarrhythmic effect after AM

130 he purpose of this study was to test whether carvedilol has an antioxidant effect in humans in vivo.

131 receptor (beta2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating G(s)-dep

132 Newer beta-blockers such as carvedilol have not been tested in this setting.

133 diotoxicity-free survival was longer on both carvedilol (hazard ratio: 0.49; 95% confidence interval:

134 c activity of our ligands, as ligands with a carvedilol head group were devoid of agonistic activity.

135 d patients entered into the Multicenter Oral Carvedilol Heart failure Assessment (MOCHA) trial, a 6-m

136 alidation and data from the Multicenter Oral Carvedilol Heart Failure Assessment Trial.

137 The 2 recent examples of the US Carvedilol Heart Failure program and the Evaluation of L

138 In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 8

139 pitalization frequency and costs in the U.S. Carvedilol Heart Failure Trials Program.

140 carvedilol (medium-dose group), or 25 mg BID carvedilol (high-dose group).

141 ely, of the patients receiving metoprolol or carvedilol (HR: 0.80 [95% CI: 0.63 to 1.00], p = 0.050).

142 With similar efficacy to carvedilol, ICL1-9 was able to promote beta2AR phosphory

143 beta-blocker treatment, including the use of carvedilol, improves myocardial betaAR signaling and red

144 There may be a differential effect of carvedilol in children and adolescents based on ventricu

145 To prospectively evaluate the effects of carvedilol in children and adolescents with symptomatic

146 hese data suggest that long-term benefits of carvedilol in heart failure are not mediated by alpha-ad

147 diated beta-arrestin1 signaling activated by carvedilol in miR biogenesis, which may be linked, in pa

148 re, we assessed the otoprotective profile of carvedilol in mouse cochlear cultures and in vivo zebraf

149 nown whether race influences the response to carvedilol in patients with chronic heart failure.

150 ed, multicenter, dose-response evaluation of carvedilol in patients with chronic stable symptomatic h

151 Predischarge initiation of carvedilol in stabilized patients hospitalized for HF im

152 in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Tria

153 ght to compare the effects of metoprolol and carvedilol in the MADIT-CRT (Multicenter Automatic Defib

154 All patients receiving either metoprolol or carvedilol in the MADIT-CRT study were identified and co

155 th beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affec

156 ng may contribute to the special efficacy of carvedilol in the treatment of heart failure and may ser

157 the effectiveness of beta-blockers, such as carvedilol, in the treatment of heart failure.

158 fications to the three principal subunits of carvedilol, including the carbazole and catechol moietie

159 Carvedilol increased myocardial glucose uptake and suppr

160 Carvedilol increased renal, hepatic, and skeletal muscle

161 riluzole; a direct antiarrhythmic action of carvedilol (independent of its alpha/beta-adrenergic blo

162 strate for the first time that nebivolol and carvedilol induce relaxation of renal glomerular microva

163 A-mediated down-regulation of MARCH2 ablated carvedilol-induced ubiquitination, endocytosis, and degr

164 wn for any Galphas-coupled receptor, whereby carvedilol induces the transition of the beta1AR from a

165 Carvedilol inhibited the activation of SAPK by 53.4 +/-

166 -initiated study to evaluate if predischarge carvedilol initiation in stabilized patients hospitalize

167 Patients were randomized to carvedilol initiation pre-hospital discharge or to postd

168 patients (91.2%) randomized to predischarge carvedilol initiation were treated with a beta-blocker,

169 Carvedilol is a uniquely effective drug for the treatmen

170 Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation

171 ta1-selective, the third-generation compound carvedilol is beta-nonselective, with ancillary pharmaco

172 non-selective beta- and alpha-blockade with carvedilol is well tolerated in patients with COPD who d

173 was found to confer greater protection than carvedilol itself in cochlear cultures and also to bind

174 heart failure outcomes in patients receiving carvedilol (low- and high-dose combined) vs placebo.

175 receive treatment with placebo, 6.25 mg BID carvedilol (low-dose group), 12.5 mg BID carvedilol (med

176 As compared with placebo, carvedilol lowered the risk of death from any cause or h

177 In response to beta blocker therapy with carvedilol, MARCH2 E3 ligase activity regulates cell sur

178 Combined treatment with enalapril and carvedilol may prevent LVSD in patients with malignant h

179 Therefore, carvedilol may reduce the risk of thromboembolic events

180 Furthermore, beta-blocker carvedilol-mediated beta-arrestin-dependent ERK activati

181 BID carvedilol (low-dose group), 12.5 mg BID carvedilol (medium-dose group), or 25 mg BID carvedilol

182 heart failure treated with beta-AR blockers (carvedilol, metoprolol, or atenolol), 9 from patients wi

183 d bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate wit

184 In subjects randomized to treatment with carvedilol (n = 231), LVEF improved 9.5 +/- 0.9 EF units

185 assigned to a group receiving enalapril and carvedilol (n = 45) or to a control group (n = 45).

186 ndomized to receive a 6.25- to 25-mg dose of carvedilol (n = 498) or 50- to 200-mg dose of metoprolol

187 nd treatment with either placebo (n=1133) or carvedilol (n=1156) for an average of 10.4 months.

188 ion of </=40% were randomly assigned 6.25 mg carvedilol (n=975) or placebo (n=984).

189 The effects of carvedilol on ejection fraction, clinical status, and ma

190 Some of the effect of carvedilol on LVEF might be mediated by improved functio

191 We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with l

192 to the beneficial effects of metoprolol and carvedilol on T-tubule remodeling.

193 to explore whether the protective effects of carvedilol on the ischemic myocardium include inhibition

194 AF, which could potentially be suppressed by carvedilol or (R)-carvedilol.

195 mains controversial, even in the wake of the Carvedilol Or Metoprolol European Trial (COMET).

196 mized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET).

197 ly substantial comparative trial to date-the Carvedilol or Metoprolol European Trial-has compared car

198 All subjects were treated with carvedilol or metoprolol for at least 3 months.

199 tor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.

200 ure were randomly assigned to receive either carvedilol or metoprolol in addition to standard therapy

201 tween all-cause mortality and treatment with carvedilol or metoprolol succinate was observed after ei

202 chronic heart failure who were using either carvedilol or metoprolol succinate were identified in th

203 , nonselective beta-adrenergic blockade with carvedilol or propranolol does not prevent patients with

204 d 23 patients with CHF who were treated with carvedilol or propranolol in addition to ACE inhibitors,

205 tion of trained patients treated with either carvedilol or propranolol increased from 12.9 +/- 1.4 to

206 gh-cholesterol diet supplemented with either carvedilol or propranolol.

207 l benefit was greater for trials of the drug carvedilol (OR 0.54, 95% CI 0.36 to 0.81) than for nonca

208 ergic-receptor blocking agent (metoprolol or carvedilol) or placebo.

209 e and then randomized to receive lisinopril, carvedilol, or placebo.

210 The superiority of carvedilol over metoprolol tartrate in one clinical tria

211 ischaemia had a greater increase in LVEF on carvedilol (p=0.0002 and p=0.009, respectively).

212 from 19+/-8.5% to 25+/-9.9% (P<0.0005) with carvedilol (P=NS between groups).

213 curred in 21% of placebo patients and 11% of carvedilol patients, reflecting a 48% (P = .008) reducti

214 975 (2.3%) in the carvedilol group, giving a carvedilol/placebo hazard ratio (HR) of 0.41 (95% confid

215 rs were equally randomized to the SCS, MEDS (carvedilol plus ramipril 2.5 mg PO QD), SCS plus MEDS (c

216 a placebo-controlled multicenter trial, the Carvedilol Post-Infarct Survival Control in Left Ventric

217 Carvedilol prevented beta(2)AR recycling, blocked recrui

218 reated with trastuzumab, both lisinopril and carvedilol prevented cardiotoxicity in patients receivin

219 Taken together, these results suggest that carvedilol prevents myocardial ischemia/reperfusion-indu

220 Carvedilol produced significant reductions in heart rate

221 iciency Bisoprolol Study (CIBIS II), and the Carvedilol Prospective Randomized Cumulative Survival St

222 vention Trial in Heart Failure), COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival tr

223 Carvedilol reduced all-cause mortality but had no effect

224 ischemic cardiomyocytes, and treatment with carvedilol reduced both the intensity of staining as wel

225 Among hospitalized patients, carvedilol reduced severity of illness during hospital a

226 Carvedilol reduced the combined risk of death or hospita

227 ed by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardio

228 Compared with placebo, carvedilol reduced the risk of hospitalization for any r

229 Carvedilol reduced the risk of worsening heart failure (

230 Carvedilol reduces disease progression in heart failure,

231 ts with heart failure have demonstrated that carvedilol reduces morbidity and mortality and inhibits

232 In addition, treatment with carvedilol resulted in a lower von Willebrand factor tha

233 Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic

234 For such patients, lisinopril or carvedilol should be considered to minimize interruption

235 tients; 24 on carvedilol and 25 on placebo), carvedilol showed attenuation of remodeling.

236 (ii) Chronic treatment with nadolol or carvedilol significantly increased beta-AR densities in

237 We conclude that carvedilol significantly inhibits ROS generation by leuk

238 We hypothesized that nebivolol and carvedilol stimulate NO release from microvascular endot

239 Some betaAR ligands, such as carvedilol, stimulate betaAR signaling preferentially th

240 non-beta-blocking carvedilol enantiomer, (R)-carvedilol, suppressed spontaneous Ca(2+) oscillations i

241 Carvedilol suppresses atrial as well as ventricular arrh

242 with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to m

243 ignificantly higher in patients treated with carvedilol than in those treated with metoprolol (20 [ra

244 (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% +/- 3.9% vs.

245 tal myocardial infarction were also lower on carvedilol than on placebo.

246 n to microalbuminuria was less frequent with carvedilol than with metoprolol (6.4% vs 10.3%; odds rat

247 sociated with higher mortality compared with carvedilol therapy (hazard ratio, 1.49; 95% confidence i

248 These changes are not attenuated by carvedilol therapy and highlight the need for developmen

249 There were no adverse effects of carvedilol therapy and no excess events in this subgroup

250 n for 2 hours 3 times a day), medicine (MED; carvedilol therapy at 12.5 mg PO BID), or control (CTRL;

251 ment Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial wa

252 We studied the effect of carvedilol therapy on myocardial FFA and glucose use in

253 rix, and apoptosis, which were refractory to carvedilol therapy.

254 With carvedilol, there was a parallel decline from 4.7+/-1.4

255 esized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking prope

256 rest or on minimal exertion, the addition of carvedilol to conventional therapy ameliorates the sever

257 ht to evaluate the efficacy of enalapril and carvedilol to prevent chemotherapy-induced left ventricu

258 suggest a potential unique clinical role of carvedilol to stimulate skeletal muscle contractility wh

259 However, carvedilol-treated dogs showed significantly greater inc

260 tly affect survival in metoprolol-treated or carvedilol-treated HF patients in this study.

261 Carvedilol-treated patients were also less likely than p

262 vehicle-treated rabbits but only one of six carvedilol-treated rabbits (P<.01).

263 h improvement in ventricular function during carvedilol treatment in heart failure patients.

264 Carvedilol treatment in patients with heart failure resu

265 After carvedilol treatment, the mean myocardial uptake rate fo

266 ng echocardiograms before and 3 months after carvedilol treatment.

267 We administered 3.125 mg of carvedilol twice daily to normal subjects for 1 week.

268 Here we show that propranolol and carvedilol, two beta-blocker drugs that inhibit beta-adr

269 In human cells and mouse hearts, carvedilol upregulates a subset of mature and pre-miRs,

270 l and placebo (isometric handgrip -3.5 U for carvedilol versus -1.2 U for metoprolol and -2.2 U for p

271 o, P=0.15; cold pressor test 3.1+/-8.9 U for carvedilol versus 9.0+/-2.7 U for metoprolol and 8.2+/-5

272 nd long-term (6 months, oral) treatment with carvedilol versus placebo in 151 consecutive patients wi

273 hat drugs targeting these receptors, such as carvedilol, warrant further investigation as novel thera

274 ic blocking or other ancillary properties of carvedilol warrants further investigation.

275 partial agonist activity at either receptor; carvedilol was a genotype-independent neutral antagonist

276 The benefit of carvedilol was apparent and of similar magnitude in both

277 class I and II and with wide QRS complexes, carvedilol was associated with a 30% reduction in hospit

278 plantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inapp

279 Treatment with carvedilol was associated with a significantly decreased

280 Treatment with carvedilol was associated with a significantly decreased

281 Compared with metoprolol, carvedilol was associated with fewer days lost to death,

282 The antiarrhythmic effect of carvedilol was examined in a placebo-controlled multicen

283 Carvedilol was found to be safe, and it significantly re

284 In primary prophylaxis of EVH, carvedilol was found to reduce the rate of initial bleed

285 Carvedilol was modestly effective in attenuating MDMA-in

286 This effect of carvedilol was not influenced by sex, age, race, cause o

287 of hibernator status on response of LVEF to carvedilol was not significant (0.7 [-2.2 to 3.5]; p=0.6

288 A novel beneficial and synergistic effect of carvedilol was seen in patients with CRT-D and LBBB.

289 to Ang II infusion in patients treated with carvedilol was significantly lower than in patients trea

290 Carvedilol was started in week 2 post MR induction and g

291 ese measures of outcome and clinical status, carvedilol was superior to placebo within each racial co

292 The maximum of NO release for nebivolol and carvedilol was very similar (188+/-14 and 226+/-17, resp

293 Carvedilol was well tolerated and safe to use in patient

294 ceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized three different

295 result, estimated inpatient care costs with carvedilol were 57% lower for cardiovascular admissions

296 Metoprolol and carvedilol were well tolerated, and both patient groups

297 Carvedilol, when added to standard therapy, including an

298 The previously reported benefits of carvedilol with regard to morbidity and mortality in pat

299 ol or Metoprolol European Trial-has compared carvedilol with short-acting metoprolol tartrate at diff

300 ed that alpha-adrenergic-blocking effects of carvedilol would limit vasoconstriction in response to a